Cart
sales@molnova.com
YM17E
CAS No. 124900-72-7
YM17E( —— )
Catalog No. M26512 CAS No. 124900-72-7
YM17E is an inhibitor of ACAT with IC50 of 44 nM in rabbit liver microsomes in vitro.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 113 | In Stock |
|
| 2MG | 52 | In Stock |
|
| 5MG | 85 | In Stock |
|
| 10MG | 117 | In Stock |
|
| 25MG | 202 | In Stock |
|
| 50MG | 291 | In Stock |
|
| 100MG | 434 | In Stock |
|
| 200MG | 622 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameYM17E
-
NoteResearch use only, not for human use.
-
Brief DescriptionYM17E is an inhibitor of ACAT with IC50 of 44 nM in rabbit liver microsomes in vitro.
-
DescriptionYM17E is an inhibitor of ACAT with IC50 of 44 nM in rabbit liver microsomes in vitro.(In Vitro):YM17E is potent in inhibiting ACAT activity in the intestine with IC50 of 34 nM.(In Vivo):YM17E inhibits the production of [14C]cholesteryloleate from [14C]oleoyl CoA in a dose-dependent manner in both liver and intestinal microsomes used as enzyme sources. YM17E (3, 5, 10 mg/kg, i.v.) significantly inhibits hepatic ACAT activities in a dose-dependent manner. YM17E (oral; i.v.) produces a significant increase in 125I-LDL clearance in atherogenic diet-fed rats. YM17E (3, 10, 30 mg/kg; p.o.) decreases total cholesterol, cholesteryl ester, and non-HDL cholesterol in a dose-dependent manner. YM17E (oral) decreases total cholesterol and cholesteryl ester levels in the liver significantly in a dose-dependent manner.
-
In VitroYM17E is as potent in inhibiting ACAT activity in the liver as in the intestine, with IC50 values of 45 and 34 nM, respectively.
-
In VivoYM17E (3, 10 and 30 mg/kg per day, p.o.) decreases total cholesterol, cholesteryl ester and non-HDL cholesterol in a dose-dependent manner. Total cholesterol and cholesteryl ester levels in liver do not decrease significantly after intravenous administration of YM17E, but do decrease significantly and in a dose-dependent manner after oral administration. YM17E (3, 5, 10 mg/kg, i.v.) significantly inhibits hepatic ACAT activities in a dose-dependent manner. YM17E produces a significant increase in 125I-LDL clearance in atherogenic diet-fed rats after both oral and intravenous administration. YM17E inhibits production of [14C]cholesteryloleate from [14C]oleoyl CoA in a dose-dependent manner in both liver and intestinal microsomes used as enzyme sources.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorHCV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number124900-72-7
-
Formula Weight652.928
-
Molecular FormulaC40H56N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 125 mg/mL (191.45 mM)
-
SMILESCN(C)c1ccc(NC(=O)N(Cc2cccc(CN(C3CCCCCC3)C(=O)Nc3ccc(cc3)N(C)C)c2)C2CCCCCC2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Makonen Belema, et al. Hepatitis C virus inhibitors. US8329159B2.
molnova catalog
related products
-
Galdosol
Galdosol is a natural product found in Perovskia abrotanoides.
-
Murrayone
Murrayone, a coumarin-containing compound extracted from M. paniculata, is the most bioactive substance in this species and is a cancer metastasis chemopreventive agent based on its unique pharmacological properties.
-
Chrysotobibenzyl
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin.
